Conclusion

Adefovir dipivoxil (Hepsera) is an excellent example of a prodrug that can overcome the oral delivery problem associated with poor permeation across the intestinal mucosa. Since its launch in 2002, Hepsera has become an important agent for the treatment of hepatitis B patients with evidence of active viral replication. A safety profile similar to placebo has been observed for Hepsera, which allows it to be prescribed as an effective drug for chronic treatment of hepatitis B.

References

1. World Health Organization. Available online at: www.who.int/csr/disease/hepatitis/whocdscsrlyo20022/en/index1.html (accessed May 2006).

2. Hepatitis. http://hepatitis.about.com/od/hepatitisnews (accessed May 2006).

4. Papatheodoridis, G. V; Hadziyannis, S. J. Aliment. Pharmacol. Ther. 2004, 19, 25-37.

5. Cundy, K. C.; Barditch-Crovo, P; Walker, R. E.; Collier, A. C.; Ebeling, D.; Toole, J. J.; Jaffe, H. S. Antimicrob. Agents Chemother. 1995, 39, 2401-2405.

6. Qaqish, R. B.; Mattes, K. A.; Ritchie, D. J. Clin. Ther. 2003, 25, 3084-3099.

7. Shaw, J.-P; Cundy, K. C. Pharm. Res. 1993, 10, S294.

8. Cundy, K. C.; Shaw, J.-P; Lee, W A. Antimicrob. Agents Chemother. 1994, 38, 365-368.

9. Naesens, L.; Neyts, J.; Balzarini, J.; Bischofberger, N.; De Clercq, E. Nucleosides Nucleotides 1995, 14, 767-770.

10. Shaw, J.-P; Louie, M. S.; Krishnamurthy, V V; Arimilli, M. N.; Jones, R. J.; Bidgood, A. M.; Lee, W A.; Cundy, K. C. DrugMetab. Dispos. 1997, 25, 362-366.

11. Peters, M. G.; Hann, H. W; Martin, P.; Heathcote, J. E.; Buggisch, P.; Rubin, R.; Bourliere, M.; Kowdley, K.; Trepo, C.; Gray, D. F et al.

Gastroenterology 2004, 126, 91-101.

12. Perrillo, R.; Hann, H.-W; Mutimer, D.; Willems, B.; Leung, N.; Lee, W M.; Moorat, A.; Gardner, S.; Woessner, M.; Bourne, E. et al. Gastroenterology 2004, 126, 81-90.

13. Cundy, K. C.; Fishback, J. A.; Shaw, J.-P.; Lee, M. L.; Soike, K. F; Visor, G. C.; Lee, W A. Pharm. Res. 1994, 11, 839-843.

14. Rivkin, A. M. Ann. Pharmacother. 2004, 38, 625-633.

15. Hepsera™ (adefovir dipivoxil) tablets. US Prescribing Information. Gilead Sciences, Inc. Foster City, CA, September 2002.

16. Tong, M. J.; Tu, S. S. Semin. Liver Dis. 2004, 24, 37-44.

17. Brunetto, M. R.; Bonino, F Curr. Pharm. Des. 2004, 10, 2063-2075.

18. Angus, P; Vaughan, R.; Xiong, S.; Yang, H.; Delaney, W; Gibbs, C.; Brosgart, C.; Colledge, D.; Edwards, R.; Ayres, A. et al. Gastroenterology 2003, 125, 292-297.

19. Kumar, R.; Agrawal, B. Curr. Opin. Invest. Drugs 2004, 5, 171-178.

20. Starrett, J. E., Jr; Tortolani, D. R.; Russell, J.; Hitchcock, M. J. M.; Whiterock, V; Martin, J. C.; Mansuri, M. M. J. Med. Chem. 1994, 37, 1857-1864.

21. Starrett, J. E., Jr; Tortolani, D. R.; Hitchcock, M. J. M.; Martin, J. C.; Mansuri, M. M. Antiviral Res. 1992, 19, 267-273.

22. Arimilli, M. N.; Lee, T T K.; Manes, L. V Nucleotide Analog Compositions. WO 99/04774, 4 February, 1999.

23. Yu, R. H.; Schultze, L. M.; Rohloff, J. C.; Dudzinski, P. W; Kelly, D. E. Org. Process Res. Dev. 1999, 3, 53-55.

24. Yuan, L.-C.; Dahl, T. C.; Iliyai, R. Pharm. Res. 2000, 17, 1098-1103.

25. Naesens, L.; Balzarini, J.; Bischofberger, N.; De Clercq, E. Antimicrob. Agents Chemother. 1996, 40, 22-28.

26. Cihlar, T; Rosenberg, I.; Votruba, I.; Holy, A. Antimicrob. Agents Chemother. 1995, 39, 117-124.

27. Olsanska, L.; Cihlar, T; Votruba, I.; Holy, H. Collect. Czech. Chem. Commun. 1997, 62, 821-828.

28. Robbins, B. L.; Greenhaw, J. J.; Connelly, M. C.; Fridland, A. Antimicrob. Agents Chemother. 1995, 39, 2304-2308.

29. Ray, A. S.; Vela, J. E.; Olson, L.; Fridland, A. Biochem. Pharmacol. 2004, 68, 1825-1831.

30. Hadziyannis, S. J.; Tassopoulos, N.; Heathcote, E. J.; Chang, T-T; Kitis, G.; Rizzetto, M.; Marcellin, P; Lim, S. G.; Goodman, Z.; Wulfsohn, M. S. et al. N. Engl. J. Med. 2003, 348, 800-807.

31. Benhamou, Y; Bochet, M.; Thibault, V; Calvez, V; Fievet, M. H.; Vig, P; Gibbs, C. S.; Brosgart, C.; Fry, J.; Namini, H. et al. Lancet 2001, 358, 718-723.

32. Marcellin, P; Chang, T-T; Lim, S. G.; Tong, M. J.; Sievert, W; Shiffman, M. L.; Jeffers, L.; Goodman, Z.; Wulfsohn, M. S.; Xiong, S. et al. N. Engl. J. Med. 2003, 348, 808-816.

Reza Oliyai, PhD, is the Director of Formulation and Process Development, Gilead Sciences. He is a co-inventor of Viread, Truvada, and the triple combination of Efavirenz/Emtricitabine/Tenofovir DF Dr Oliyai has also been involved with the development of Hepsera and Tamiflu. Dr Oliyai received his PhD from the University of Kansas in Pharmaceutical Chemistry and his BS in Pharmacy from Oregon State University.

Maria Fardis, PhD, has been at Gilead since 2001. Dr Fardis has been involved in multiple projects at Gilead ranging from immunology to antivirals. Prior to Gilead, Dr Fardis was at Intrabiotics Pharmaceuticals where she was involved in antibacterial programs. Dr Fardis received her PhD from University of California, Berkeley and her BS degree in Chemistry at the University of Illinois, Urbana-Champaign.

Biographies

Reza Oliyai Photos

& 2007 Elsevier Ltd. All Rights Reserved

No part of this publication may be reproduced, stored in any retrieval system or transmitted in any form by any means electronic, electrostatic, magnetic tape, mechanical, photocopying, recording or otherwise, without permission in writing from the publishers

Comprehensive Medicinal Chemistry II ISBN (set): 0-08-044513-6

Dealing With Back Pain

Dealing With Back Pain

Deal With Your Pain, Lead A Wonderful Life An Live Like A 'Normal' Person. Before I really start telling you anything about me or finding out anything about you, I want you to know that I sympathize with you. Not only is it one of the most painful experiences to have backpain. Not only is it the number one excuse for employees not coming into work. But perhaps just as significantly, it is something that I suffered from for years.

Get My Free Ebook


Post a comment